REPORT FROM CHINA INTERVENTIONAL THERAPEUTICS CONFERENCE

The 12th China Interventional Therapeutics Conference (CIT) was hosted at the Shanghai Convention & Exhibition Centre of International Sourcing March 20th-23rd 2014.

REFLOW MEDICAL AND MICROPORT SCIENTIFIC ANNOUNCE CHINESE ALLIANCE

ReFlow Medical, Inc. (ReFlow) today announced that it has signed an exclusive distribution and sales agreement for ReFlow’s suite of peripheral chronic total occlusion (CTO) products with MicroPort Endovascular.

INTERNATIONAL CUSTOMERS VISITED MICROPORT DURING CIT

March 20th, international business department invited nearly 160 international surgeons and clients from 14 countries to the Corporate Innovation & Commercialization Base of MicroPort.

“微创” AND “MICROPORT” WERE RECOGNIZED AS “CHINA’S NATIONAL WELL-KNOWN TRADEMARK”

Recently, “微创” and “MicroPort” were recognized as the “China’s National Well-known Trademark”. Ms. Qinyi Bian, the Senior Vice President of Corporate Affairs and Public Relations, stated, “Reputation, trust and accountability are vitally important to our success.

THE 2ND BOARD MEETING IN 2014

The 2nd meeting of the board of directors (the “Board”) of MicroPort Scientific Corporation (“MPSC”) and Shanghai MicroPort Medical (Group) Co., Ltd (the “MPSH”) was held at the conference room of No. 501 Newton Rd, ZJ Hi-Tech Park, Shanghai on 31 March 2014.
Report From China Interventional Therapeutics Conference

The 12th China Interventional Therapeutics Conference (CIT) was hosted at the Shanghai Convention & Exhibition Centre of International Sourcing March 20th-23rd 2014. MicroPort was pleased to launch our third generation DES Firehawk® Rapamycin Target Eluting Coronary Stent at the event, which represents the largest coronary intervention conference in China.

On 21 March, there was a luncheon satellite symposium sponsored by MicroPort: "The era of Target Eluting Stent: update on Firehawk preclinical and clinical program". The meeting was chaired by Dr. Run-Lin Gao, Martin B Leon, Weifeng Shen, Alexandra Lansky and Shangyu Wen. There were several keynoted speeches presented by honored opinion leaders and panel discussion with audience Q&A. The luncheon satellite symposium proved a popular event at the conference.

During the four-day conference, there were many live case transmissions, with feature lectures from varies key hospitals. In total 32 Firehawk® stents were implanted for 14 patients. During the procedures at Nanjing First Hospital, the operator adopted DK-Crush technique and implanted 2 Firehawk® stents. Firehawk® perfect trafficability, great support, and branch protection ability were recognized by the operation demonstrator and experts again.

There were several technical breakthroughs with the development of Firehawk®:
• It is the first novel abluminal groove stent in the world.
• It achieves the lowest standard of effective drug dosage in the world.
• Target study is the first pre-market study in accordance with issued by CFDA in China.
• It is the first stent to have the same efficacy and safety as Xience V, which is acknowledged as the most popular stent system worldwide.
• It is the first domestic coronary stent that would be possibly shortened DAPT.
Firehawk® Launch Ceremony

In the evening of 21 March, the Firehawk® launch ceremony was held in Marriott Shanghai Changfeng Park. There were over 400 physicians and business partners from around the world in attendance. Chairman and CEO, Dr Zhaohua Chang, the Co-Principal Investigator of TARGET, Dr. Runlin Gao and Dr. Gregg W. Stone initiated the launch of Firehawk®. The evening was a great success and MicroPort would like to thank all those involved with Firehawk®.

ReFlow Medical and MicroPort Scientific Announce Chinese Alliance

SAN CLEMENTE, Calif. & SHANGHAI--ReFlow Medical, Inc. (ReFlow) today announced that it has signed an exclusive distribution and sales agreement for ReFlow's suite of peripheral chronic total occlusion (CTO) products with MicroPort Endovascular (MicroPort Endo), a division of MicroPort Scientific Corporation (MicroPort), a leading medical device company in China.

ReFlow has developed a suite of products to cost-effectively address unmet needs in the CTO market. ReFlow’s Wingman crossing catheter is 510(k) cleared and CE Marked to be used in conjunction with steerable guidewires to access discrete regions of the peripheral vasculature and enable rapid, routine, off-the-shelf lesion crossing. The Wingman is the first of several new product families to address the clinical challenges of the CTO market that ReFlow plans to introduce around the world.

"MicroPort’s successful history of obtaining timely regulatory approvals, launching new products, and rapidly expanding market share makes it an ideal partner for us in China," Isa Rizk, President and CEO of ReFlow, said. "We look forward to working with MicroPort to develop this important market and to drive market adoption of ReFlow's products."

Zhonghua Li, Executive Vice General Manager of MicroPort Endo, commented that, "We are very pleased to have entered into this long-term distribution agreement with ReFlow. ReFlow’s products provide a unique solution to addressing the growing CTO opportunity in China with a cost-effective, and easy-to-use solution."
International Customers Visited MicroPort during CIT

March 20th, international business department invited nearly 160 international surgeons and clients from 14 countries to the headquarter and the Corporate Innovation & Commercialization Base of MicroPort. In the evening, there was a party “MicroPort Night” held and all the participants were excited about the launch of Firehawk® and showing great confidence in the worldwide introduction of the product.

"微创" and "MicroPort" were Recognized as "China's National Well-known Trademark"

Recently, "微创" and "MicroPort" were recognized as the "China's National Well-known Trademark". Ms. Qinyi Bian, the Senior Vice President of Corporate Affairs and Public Relations, stated, "Reputation, trust and accountability are vitally important to our success. We are determined in our endeavor to build on the respect we have gained and the value of our company as an outstanding enterprise."

We strive to provide the highest quality medical devices and excellent service and create a unique company that is a recognized "Global Brand Belonging to Patients and Doctors".

The 2nd Board Meeting in 2014

The 2nd meeting of the board of directors (the “Board”) of MicroPort Scientific Corporation (“MPSC”) and Shanghai MicroPort Medical (Group) Co., Ltd (the “MPSH”) was held at the conference room of No. 501 Newton Rd, ZJ Hi-Tech Park, Shanghai on 31 March 2014 and final dividend proposal were approved. The Annual Result Announcement for the fiscal year ended 31 December 2013 was released after the meeting.